InvestSMART

Rhythm Biosciences Limited (ASX:RHY)

ALERT: Price-sensitive ASX Announcement for RHY
Current share price for RHY : $0.110 0.01 (10%)+
Announcement
Release
28 Aug 2025 9:31AM
Price at Release
$0.100
Full Release
download
Summary
Rhythm Biosciences Limited (RHY) announced a formal strategic partnership with the Know Your Lemons Foundation, a leading global breast cancer education charity. The partnership aims to enhance awareness and education about breast cancer, leveraging Know Your Lemons Foundation’s recognized campaigns and extensive reach across more than 100 countries. Through this collaboration, RHY will contribute to global efforts in early detection and cancer education, supporting both parties’ goals in advancing women’s health. The announcement details the mutual benefits, such as increased visibility for RHY’s diagnostic innovations and Know Your Lemons Foundation’s capacity to broaden its educational initiatives. The partnership is expected to create value by combining RHY’s expertise in diagnostics with the Foundation’s educational platforms, ultimately improving outcomes in breast cancer awareness and early detection.
Key Points
  • Rhythm Biosciences Limited announced a strategic partnership with Know Your Lemons Foundation.
  • Know Your Lemons Foundation is a global leader in breast cancer education with programs in over 100 countries.
  • The partnership aims to increase awareness and education for breast cancer.
  • RHY will leverage the Foundation’s campaigns and educational reach to support early detection.
  • The collaboration aligns with both organizations’ missions to advance women’s health.
  • Benefits include increased exposure for RHY’s diagnostic products and enhanced educational outreach for Know Your Lemons Foundation.
  • The partnership is positioned to add value by merging RHY’s diagnostics expertise with the Foundation’s education efforts.
  • The announcement underscores both parties’ roles in improving breast cancer outcomes through awareness and innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.